$NYXH

Publication relating to transparency notifications

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) said it received EU transparency notifications. Orin Hirchman-controlled entities acquired voting securities, raising voting rights to 14,534,880 (14.55%) vs a 10% threshold, effective June 10, 2026. Resmed Inc. reported a passive downward crossing below 3%, holding 1,943,828 voting rights (1.95%).

Original reporting
Published Jun 29, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Publication relating to transparency notifications — source image
Decision brief

The 30-second read

$NYXHNeutralLow
01

Why it matters

The article discloses two holder-related events: (1) Orin Hirchman/AIGH-controlled entities crossing above 10% voting rights (14.55% total), and (2) Resmed Inc. passively crossing below the 3% lowest threshold (down to 1.95%).

02

Market read

Ownership/control signals can matter for small/mid-cap risk premia, but this disclosure lacks new operational or financial information.

03

What to watch

Voting-rights percentages are based on a specific denominator date (June 10, 2026); changes in total shares can mechanically move percentages without altering economic exposure.

Relevance 5/10Novelty 5/10Timing: after-hours/dated June 29, 2026 transparency notification referencing a June 10, 2026 threshold cross

Background

Nyxoah SA reports transparency notifications under the EU/Belgian large shareholding disclosure framework, detailing voting-rights threshold crossings.

Company-level read

Ticker impact

$NYXHNeutralMedium confidence
Context

Nyxoah discloses transparency notifications showing Orin Hirchman/AIGH entities crossed the 10% voting-rights threshold on June 10, 2026.

Expected impact

Likely limited/short-lived price impact; watch for follow-through in ownership/control expectations rather than fundamentals.

Evidence & confidence

The filing provides a concrete ownership/voting-rights change (14.55% total) but no new guidance, deal, or enforcement action.

Market effects

No sector-wide read-across; this is company-specific ownership disclosure.

Primarily relevant to Euronext Brussels/Nasdaq NYXH holders; limited broader regional spillover.

Low global relevance; transparency notification without cross-border deal/regulatory action.

Counterpoint

A threshold-crossing transparency notice may reflect passive/administrative changes rather than a new strategic stance, so price reaction can fade quickly.

Key entities

  • Nyxoah SA

    Subject of the transparency notification; voting-rights threshold changes are reported for its shareholders.

  • Orin Hirchman / AIGH Capital Management LLC

    Reported acquisition of voting securities by entities it controls, reaching 14.55% voting rights.

  • Resmed Inc.

    Reported passive downward crossing below the 3% voting-rights threshold to 1.95%.

Related articles

$NYXHMed

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.

$NYXHMed

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.

$NYXHMedAI 8/10

Nyxoah Announces Closing of Underwritten Public Offering

Nyxoah SA said it has closed its previously announced underwritten U.S. public offering, selling 55,232,558 ordinary shares at $1.72 (EUR 1.48) each. Gross proceeds are about $95.0 million (EUR 81.9 million). Net proceeds will fund U.S. commercialization, Genio R&D and commercialization, and general corporate purposes; the company also plans to draw EUR 13.8 million from its EIB loan tranche in Q2 2026.

$NYXHMedAI 8/10

Benzinga

Nyxoah SA (NASDAQ:NYXH) shares rose in Tuesday premarket but are down nearly 70% YTD. The company priced a $95 million underwritten public offering of about 55.2 million shares at $1.72 each, with a 30-day over-allotment option. Proceeds will fund U.S. commercialization and Genio R&D. Nyxoah also began a CEO transition search. In Q1, it reported a 43¢ loss and $7.46M sales; FY2026 sales guidance is $42.16M–$46.84M.